Status:
COMPLETED
Celiac Disease Diagnosis in Patients With Weakly Positive Serum Anti-Transglutaminase: Duodenal Anti-Endomysium Assay.
Lead Sponsor:
University of Palermo
Conditions:
Celiac Disease
Eligibility:
All Genders
18-70 years
Brief Summary
Celiac disease (CD) is a chronic immune-mediated disorder that occurs in genetically predisposed populations. Patients affected by the disease may be asymptomatic or manifest classic malabsorption sym...
Detailed Description
Celiac disease (CD) is a chronic immune-mediated disorder that occurs in genetically predisposed populations. Patients affected by the disease may be asymptomatic or manifest classic malabsorption sym...
Eligibility Criteria
Inclusion
- adult patients, both genders, aged between 18-70 years;
- with suspected CD (i.e. affected with one or more of the following symptoms: chronic diarrhea or constipation, alternating bowel habits, abdominal pain, dyspepsia, recurrent aphthosis, dental enamel defects, thyroiditis, dermatitis, osteoporosis, joints pain, weight loss, anemia, cryptogenetic hypertransaminasemia);
- with weakly positive \[e.g. 2-3xN\] serum anti-tTG antibodies; and d) subjects with a family history of CD.
Exclusion
- \- patients with IgA deficiency, type 1 diabetes, inflammatory bowel diseases (Crohn's disease or ulcerative colitis), Helicobacter pylori infection and other gastrointestinal infection, and pregnancy.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02242123
Start Date
January 1 2012
End Date
June 1 2020
Last Update
October 8 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Internal Medicine Department of the Hospital of Sciacca (Agrigento)
Sciacca, Agrigento, Italy, 92019
2
Internal Medicine Department of the University Hospital of Palermo
Palermo, Italy, 90127